174 related articles for article (PubMed ID: 32901849)
1. Targeting CDK9: A novel biomarker in the treatment of endometrial cancer.
He S; Fang X; Xia X; Hou T; Zhang T
Oncol Rep; 2020 Nov; 44(5):1929-1938. PubMed ID: 32901849
[TBL] [Abstract][Full Text] [Related]
2. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer.
Wang J; Dean DC; Hornicek FJ; Shi H; Duan Z
FASEB J; 2019 May; 33(5):5990-6000. PubMed ID: 30726104
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase 9 promotes cervical cancer development via AKT2/p53 pathway.
Xu J; Xu S; Fang Y; Chen T; Xie X; Lu W
IUBMB Life; 2019 Mar; 71(3):347-356. PubMed ID: 30536701
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma.
Ma H; Seebacher NA; Hornicek FJ; Duan Z
EBioMedicine; 2019 Jan; 39():182-193. PubMed ID: 30579871
[TBL] [Abstract][Full Text] [Related]
5. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
[TBL] [Abstract][Full Text] [Related]
6. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.
Albert TK; Rigault C; Eickhoff J; Baumgart K; Antrecht C; Klebl B; Mittler G; Meisterernst M
Br J Pharmacol; 2014 Jan; 171(1):55-68. PubMed ID: 24102143
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
8. USP14 is a predictor of recurrence in endometrial cancer and a molecular target for endometrial cancer treatment.
Vogel RI; Pulver T; Heilmann W; Mooneyham A; Mullany S; Zhao X; Shahi M; Richter J; Klein M; Chen L; Ding R; Konecny G; Kommoss S; Winterhoff B; Ghebre R; Bazzaro M
Oncotarget; 2016 May; 7(21):30962-76. PubMed ID: 27121063
[TBL] [Abstract][Full Text] [Related]
9. Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma.
Li X; Seebacher NA; Xiao T; Hornicek FJ; Duan Z
J Orthop Res; 2019 Feb; 37(2):510-521. PubMed ID: 30488489
[TBL] [Abstract][Full Text] [Related]
10. CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression.
Mitra P; Yang RM; Sutton J; Ramsay RG; Gonda TJ
Oncotarget; 2016 Feb; 7(8):9069-83. PubMed ID: 26812885
[TBL] [Abstract][Full Text] [Related]
11. CDK9 inhibitors in acute myeloid leukemia.
Boffo S; Damato A; Alfano L; Giordano A
J Exp Clin Cancer Res; 2018 Feb; 37(1):36. PubMed ID: 29471852
[TBL] [Abstract][Full Text] [Related]
12. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.
Wang X; Yu C; Wang C; Ma Y; Wang T; Li Y; Huang Z; Zhou M; Sun P; Zheng J; Yang S; Fan Y; Xiang R
Eur J Med Chem; 2019 Nov; 181():111535. PubMed ID: 31376566
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9.
Itkonen HM; Poulose N; Steele RE; Martin SES; Levine ZG; Duveau DY; Carelli R; Singh R; Urbanucci A; Loda M; Thomas CJ; Mills IG; Walker S
Mol Cancer Res; 2020 Oct; 18(10):1512-1521. PubMed ID: 32611550
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor.
Lim SL; Xu L; Han BC; Shyamsunder P; Chng WJ; Koeffler HP
PLoS One; 2020; 15(6):e0232068. PubMed ID: 32559187
[TBL] [Abstract][Full Text] [Related]
15. The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression.
Hou T; Ray S; Brasier AR
J Biol Chem; 2007 Dec; 282(51):37091-102. PubMed ID: 17956865
[TBL] [Abstract][Full Text] [Related]
16. Serum cyclin-dependent kinase 9 is a potential biomarker of atherosclerotic inflammation.
Han Y; Zhao S; Gong Y; Hou G; Li X; Li L
Oncotarget; 2016 Jan; 7(2):1854-62. PubMed ID: 26636538
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of Sam68 expression in endometrial carcinoma.
Wang Q; Li Y; Zhou J; Liu J; Qin J; Xing F; Zhang J; Cheng J
Tumour Biol; 2015 Jun; 36(6):4509-18. PubMed ID: 25874492
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma.
Narita T; Ishida T; Ito A; Masaki A; Kinoshita S; Suzuki S; Takino H; Yoshida T; Ri M; Kusumoto S; Komatsu H; Imada K; Tanaka Y; Takaori-Kondo A; Inagaki H; Scholz A; Lienau P; Kuroda T; Ueda R; Iida S
Blood; 2017 Aug; 130(9):1114-1124. PubMed ID: 28646117
[TBL] [Abstract][Full Text] [Related]
19. Targeting CDK9 for treatment of colorectal cancer.
Rahaman MH; Lam F; Zhong L; Teo T; Adams J; Yu M; Milne RW; Pepper C; Lokman NA; Ricciardelli C; Oehler MK; Wang S
Mol Oncol; 2019 Oct; 13(10):2178-2193. PubMed ID: 31398271
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase 9 is required for tumor necrosis factor-alpha-stimulated matrix metalloproteinase-9 expression in human lung adenocarcinoma cells.
Shan B; Zhuo Y; Chin D; Morris CA; Morris GF; Lasky JA
J Biol Chem; 2005 Jan; 280(2):1103-11. PubMed ID: 15528190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
